Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	FLT1	Synonyms	FLT, FLT-1, VEGFR-1, VEGFR1	Type of gene	protein-coding
Chromosome	13	Map location	13q12.3	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	fms related receptor tyrosine kinase 1

GTO ID	GTC0032
Trial ID	NCT00395057
Disease	Age-Related Macular Degeneration
Altered gene	FLT1
Therapeutic/Target gene	Target gene
Therapy	siRNA
Treatment	AGN211745\|Sirna-027
Phase	Phase2
Recruitment status	Terminated
Title	A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
Year	2007
Country	United States\|Australia\|Philippines
Company sponsor	Allergan
Other ID(s)	211745-001

Clinical Result

Cohort1: AGN 211745_dose level 1

Administration route	None
Dosage	AGN 211745 Solution, 1000µg, at Day 1, Month 1, Month 2
Pts	34
Age	Adult, Older_Adult
Outcome	Percentage of Patients With Improvement in Best Corrected Visual Acuity (BCVA) of 15 or More Letters at Month 3:Measure Type: Number:5.9
Adverse reactions	4/34(Neoplasms benign, malignant and unspecified(incl cysts and polyps); Vascular disorders)

Cohort2: AGN 211745_dose level 2

Administration route	None
Dosage	AGN 211745 Solution, 300µg, at Day 1, Month 1, Month 2
Pts	35
Age	Adult, Older_Adult
Outcome	Percentage of Patients With Improvement in Best Corrected Visual Acuity (BCVA) of 15 or More Letters at Month 3:Measure Type: Number:2.9
Adverse reactions	3/35(Cardiac disorders; Nervous system disorders; Reproductive system and breast disorders)

Cohort3: AGN 211745_dose level 3

Administration route	None
Dosage	AGN 211745 Solution, 100µg, at Day 1, Month 1, Month 2
Pts	35
Age	Adult, Older_Adult
Outcome	Percentage of Patients With Improvement in Best Corrected Visual Acuity (BCVA) of 15 or More Letters at Month 3:Measure Type: Number:0
Adverse reactions	3/35(Gastrointestinal disorders; Infections and infestations)

Cohort4: Ranibizumab

Administration route	None
Dosage	Ranibizumab, 500µg, at Day 1, Month 1, Month 2
Pts	34
Age	Adult, Older_Adult
Outcome	Percentage of Patients With Improvement in Best Corrected Visual Acuity (BCVA) of 15 or More Letters at Month 3:Measure Type: Number:17.6
Adverse reactions	9/34(Cardiac disorders; Hepatobiliary disorders; Infections and infestations; Metabolism and nutrition disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Vascular disorders)

Relationship Graph

Overview of Knowledge Graph